Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ischemic Heart Disease

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 61 articles:
HTML format



Single Articles


    November 2021
  1. TEMIZ-RESITOGLU M, Guden DS, Senol SP, Vezir O, et al
    Pharmacological inhibition of mTOR attenuates DOCA-salt-induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation and cardiovascular hypertrophy in male rats.
    J Cardiovasc Pharmacol. 2021 Nov 23. pii: 00005344-900000000-98105.
    PubMed     Abstract available


  2. WINGLER LM, Feld AP
    Nanobodies as probes and modulators of cardiovascular GPCRs.
    J Cardiovasc Pharmacol. 2021 Nov 19. pii: 00005344-900000000-98107.
    PubMed     Abstract available


  3. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    PubMed     Abstract available


  4. GRAGNANO F, Calabro P, Cattano D
    CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach?
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98112.
    PubMed    


  5. CATURANO A, Spiezia S, Sasso FC
    Statin effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Haemodialysis.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98118.
    PubMed    


    October 2021
  6. ZHANG Y, Zhao X, Ye Y, Li Q, et al
    Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98125.
    PubMed     Abstract available


  7. MELITA H, Manolis AA, Manolis TA, Manolis AS, et al
    Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    J Cardiovasc Pharmacol. 2021 Oct 20. pii: 00005344-900000000-98128.
    PubMed     Abstract available


  8. HORIKOSHI T, Nakamura T, Yoshizaki T, Nakamura J, et al
    Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98138.
    PubMed     Abstract available


  9. ASSMANN AK, Goschmer D, Sugimura Y, Chekhoeva A, et al
    A role for peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists in counteracting the degeneration of cardiovascular grafts.
    J Cardiovasc Pharmacol. 2021 Oct 4. pii: 00005344-900000000-98134.
    PubMed     Abstract available


    September 2021
  10. DU X, Ma Z, Li L, Zhong X, et al
    Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
    J Cardiovasc Pharmacol. 2021;78:e675-e680.
    PubMed     Abstract available


  11. WANG S, Li L, Deng W, Jiang M, et al
    CircRNA MFACR is upregulated in myocardial infarction and downregulates miR-125b to promote cardiomyocyte apoptosis induced by hypoxia.
    J Cardiovasc Pharmacol. 2021 Sep 13. pii: 00005344-900000000-98152.
    PubMed     Abstract available


  12. WEI H, Xue Q, Sun L, Lv J, et al
    BRD4 inhibition protects against myocardial ischemia/reperfusion injury by suppressing inflammation and oxidative stress through PI3K/AKT signaling pathway.
    J Cardiovasc Pharmacol. 2021 Sep 8. pii: 00005344-900000000-98150.
    PubMed     Abstract available


    August 2021
  13. DIAZ-CANESTRO C, Xu A
    The impact of different adipose depots on cardiovascular disease.
    J Cardiovasc Pharmacol. 2021 Aug 19. pii: 00005344-900000000-98098.
    PubMed     Abstract available


    July 2021
  14. LI Y, Meng W, Hou Y, Li D, et al
    Dual Role of Mitophagy in Cardiovascular Diseases.
    J Cardiovasc Pharmacol. 2021;78:e30-e39.
    PubMed     Abstract available


    June 2021
  15. HAMMOUD S, Kurdi M, van den Bemt BJ
    Impact of Fasting on Cardiovascular Outcomes in Patients with Hypertension.
    J Cardiovasc Pharmacol. 2021 Jun 29. pii: 00005344-900000000-98181.
    PubMed     Abstract available


  16. HAO L, Wang J, Bi SJ, Cheng C, et al
    Upregulation of lncRNA FGD5-AS1 ameliorates myocardial ischemia/reperfusion injury via miR-106a-5p and miR-106b-5p.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98185.
    PubMed     Abstract available


  17. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    PubMed     Abstract available


  18. ZHANG J, Tang Y, Zhang J, Wang J, et al
    CircRNA ACAP2 is overexpressed in myocardial infarction and promotes the maturation of miR-532 to induce the apoptosis of cardiomyocyte.
    J Cardiovasc Pharmacol. 2021 Jun 15. pii: 00005344-900000000-98198.
    PubMed     Abstract available


  19. LI Y, Ren X, Fang Z
    Systematic Review and Meta-analysis: The Effects of Prophylactic Proton Pump Inhibitor Treatment in Patients With Coronary Heart Disease Receiving Dual Antiplatelet Therapy.
    J Cardiovasc Pharmacol. 2021;77:835-861.
    PubMed     Abstract available


  20. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available


    May 2021
  21. LIU X, Hua Y, Hu M, Wu K, et al
    Knockdown of lncRNA Abhd11os attenuates myocardial ischemia/reperfusion injury by inhibiting apoptosis in cardiomyocytes.
    J Cardiovasc Pharmacol. 2021 May 31. pii: 00005344-900000000-98212.
    PubMed     Abstract available


  22. IQBAL J, Chamberlain J, Alfaidi M, Hughes M, et al
    Carbon monoxide releasing molecule A1 reduces myocardial damage after acute myocardial infarction in a porcine model.
    J Cardiovasc Pharmacol. 2021 May 20. pii: 00005344-900000000-98224.
    PubMed     Abstract available


  23. YUAN JL, Yin CY, Li YZ, Song S, et al
    EZH2 as an epigenetic regulator of cardiovascular development and diseases.
    J Cardiovasc Pharmacol. 2021 May 19. pii: 00005344-900000000-98225.
    PubMed     Abstract available


  24. CATURANO A
    Bivalirudin use for Primary Percutaneous Coronary Intervention on Long term Mortality.
    J Cardiovasc Pharmacol. 2021 May 5. pii: 00005344-900000000-98249.
    PubMed    


  25. YANG T, Gu J, Du C, Shan T, et al
    Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review.
    J Cardiovasc Pharmacol. 2021;77:549-556.
    PubMed     Abstract available


    April 2021
  26. JAGADISH PS, Le FK, Labroo A, Nasr A, et al
    A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long term Mortality.
    J Cardiovasc Pharmacol. 2021 Apr 22. pii: 00005344-900000000-98253.
    PubMed     Abstract available


  27. PENG Q, Li L, Bi X
    Long non-coding RNA SNHG7 knockdown protects mouse cardiac fibroblasts against myocardial infarction by regulating miR-455-3p/PTAFR axis.
    J Cardiovasc Pharmacol. 2021 Apr 21. pii: 00005344-900000000-98257.
    PubMed     Abstract available


  28. SALLAM MY, El-Gowilly SM, El-Mas MM
    Cardiac and brainstem neuroinflammatory pathways account for androgenic incitement of cardiovascular and autonomic manifestations in endotoxic male rats.
    J Cardiovasc Pharmacol. 2021 Apr 9. pii: 00005344-900000000-98265.
    PubMed     Abstract available


  29. LU Y, Yuan W, Wang L, Ning M, et al
    Contribution of lncRNA CASC8, CASC11 and PVT1 genetic variants to the susceptibility of coronary heart disease.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98242.
    PubMed     Abstract available


  30. JIAO F, Varghese K, Wang S, Liu Y, et al
    Recent Insights into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98240.
    PubMed     Abstract available



  31. Essential Role of the ELABELA-APJ Signaling Pathway in Cardiovascular System Development and Diseases: Erratum.
    J Cardiovasc Pharmacol. 2021;77:529.
    PubMed    


  32. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    PubMed     Abstract available


  33. YASHIMA F, Inohara T, Nishida H, Shimoji K, et al
    In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
    J Cardiovasc Pharmacol. 2021;78:221-227.
    PubMed     Abstract available


    February 2021
  34. VILHENA JC, Lopes de Melo Cunha L, Jorge TM, de Lucena Machado M, et al
    Acai reverses adverse cardiovascular remodeling in renovascular hypertension: a comparative effect with Enalapril.
    J Cardiovasc Pharmacol. 2021 Feb 19. pii: 00005344-900000000-98275.
    PubMed     Abstract available


  35. ZEYI Z, Ou C
    Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98271.
    PubMed     Abstract available


  36. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available


  37. ZHANG C, Jin DD, Wang XY, Lou L, et al
    Key Enzymes for the Mevalonate Pathway in the Cardiovascular System.
    J Cardiovasc Pharmacol. 2021;77:142-152.
    PubMed     Abstract available


    January 2021
  38. GRAGNANO F, Calabro P, Cattano D
    Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise.
    J Cardiovasc Pharmacol. 2021 Jan 13. pii: 00005344-900000000-98288.
    PubMed    


  39. LEMOINE MD, Christ T
    Human induced pluripotent stem cell derived cardiomyocytes: the new working horse in cardiovascular pharmacology?
    J Cardiovasc Pharmacol. 2021;Publish Ahead of Print.
    PubMed    


  40. KAKAVAND H, Aghakouchakzadeh M, Coons J, Talasaz AH, et al
    Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    December 2020
  41. CORDERO A, Ferreiro JL, Bertomeu-Gonzalez V, Rodriguez-Manero M, et al
    Direct oral anticoagulants vs. vitamin K antagonist after percutaneous coronary interventions in patients with atrial fibrillation: a metanalysis of cardiac ischemic events.
    J Cardiovasc Pharmacol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  42. ABDU FA, Liu L, Mohammed AQ, Xu B, et al
    Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    J Cardiovasc Pharmacol. 2020;76:678-683.
    PubMed     Abstract available


    November 2020
  43. WANG R, Peng L, Lv D, Shang F, et al
    Leonurine Attenuates Myocardial Fibrosis through Upregulation of miR-29a-3p in Mice Post-myocardial Infarction.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000957.
    PubMed     Abstract available


  44. NORDBECK P, Hu K
    The trend is your friend: DOACs as standard anticoagulants for patients with atrial fibrillation undergoing percutaneous coronary interventions.
    J Cardiovasc Pharmacol. 2020 Nov 3. doi: 10.1097/FJC.0000000000000950.
    PubMed    


  45. HUANG B, Xu C, Liu H, Deng W, et al
    In-Hospital Management and Outcomes of Acute Myocardial Infarction Before and During the Coronavirus Disease 2019 Pandemic.
    J Cardiovasc Pharmacol. 2020;76:540-548.
    PubMed     Abstract available


  46. MA H, Zheng L, Qin H, Wang W, et al
    Myocardial Infarction-associated Transcript Knockdown Inhibits Cell Proliferation, Migration, and Invasion Through miR-490-3p/Intercellular Adhesion Molecule 1 Axis in Oxidized Low-density Lipoprotein-induced Vascular Smooth Muscle Cells.
    J Cardiovasc Pharmacol. 2020;76:617-626.
    PubMed     Abstract available


  47. BHATTARAI M, Ibrahim AM, Salih M, Tandan N, et al
    Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Cont
    J Cardiovasc Pharmacol. 2020;76:574-583.
    PubMed     Abstract available


    October 2020
  48. ZHANG P, Yu Y, Wang P, Shen H, et al
    Role of Hydrogen Sulfide in Myocardial Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000943.
    PubMed     Abstract available


  49. SANGWOO P, Yong-Giun K, Soe Hee A, Hyun Woo P, et al
    Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker Based Optimal Medical Therapy after Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000930.
    PubMed     Abstract available


  50. CALCAGNO S, Di Pietro R, Biondi-Zoccai G, Versaci F, et al
    Renin-angiotensin blocking therapies: a must - but how? - after percutaneous coronary intervention.
    J Cardiovasc Pharmacol. 2020 Oct 23. doi: 10.1097/FJC.0000000000000941.
    PubMed    


  51. MUHAMMAD HAISUM M, Mahboob A, Dan A, Yochai B, et al
    Efficacy of Long-term Oral Beta-blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction with Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000922.
    PubMed     Abstract available


  52. QIU M, Ding LL, Wei XB, Liu SY, et al
    Comparative efficacy of GLP-1 RAs and SGLT2is for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000916.
    PubMed     Abstract available


  53. NAJAFIPOUR H, Rostamzadeh F, Yeganeh-Hajahmadi M, Joukar S, et al
    Improvement of cardiac function in rats with myocardial infarction by low- to moderate-intensity endurance exercise is associated with normalization of Klotho and SIRT1.
    J Cardiovasc Pharmacol. 2020 Oct 15. doi: 10.1097/FJC.0000000000000935.
    PubMed     Abstract available


  54. ZHANG Y, Wen W, Liu H
    The Role of Immune Cells in Cardiac Remodeling After Myocardial Infarction.
    J Cardiovasc Pharmacol. 2020;76:407-413.
    PubMed     Abstract available


  55. ORTIZ VD, Turck P, Teixeira R, Bello-Klein A, et al
    Effects of carvedilol and thyroid hormones co-administration on apoptotic and survival proteins in the heart following acute myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Oct 1. doi: 10.1097/FJC.0000000000000923.
    PubMed     Abstract available


  56. KRAUS L, Mohsin S
    Role of Stem Cell Derived Microvesicles in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2020 Oct 1. doi: 10.1097/FJC.0000000000000920.
    PubMed     Abstract available


    September 2020
  57. WANG Q, Liang C
    The Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients with Acute Coronary Syndrome.
    J Cardiovasc Pharmacol. 2020 Sep 24. doi: 10.1097/FJC.0000000000000914.
    PubMed     Abstract available


    August 2020
  58. MCGINLEY C, Mordi IR, Kelly P, Currie P, et al
    Prehospital Administration of Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Is Associated With Improved Long-Term Survival.
    J Cardiovasc Pharmacol. 2020;76:159-163.
    PubMed     Abstract available


  59. LIN Y, Huang S, Chen Y, Wu Z, et al
    Helix B Surface Peptide Protects Cardiomyocytes From Hypoxia/Reoxygenation-induced Autophagy Through the PI3K/Akt Pathway.
    J Cardiovasc Pharmacol. 2020;76:181-188.
    PubMed     Abstract available


    May 2020
  60. COLAREDA GA, Ragone MI, Bonazzola P, Consolini AE, et al
    The mKATP Channels and protein-kinase C Are Involved in the Cardioprotective Effects of Genistein on Estrogen-Deficient Rat Hearts Exposed to Ischemia/Reperfusion: Energetic Study.
    J Cardiovasc Pharmacol. 2020;75:460-474.
    PubMed     Abstract available


    April 2020
  61. ZHOU TT, Wang XY, Huang J, Deng YZ, et al
    Mitochondrial Translocation of DJ-1 Is Mediated by Grp75: Implication in Cardioprotection of Resveratrol Against Hypoxia/Reoxygenation-Induced Oxidative Stress.
    J Cardiovasc Pharmacol. 2020;75:305-313.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: